Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta …
Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …
Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis
Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a
network meta‐analysis - Kew, KM - 2014 | Cochrane Library Skip to Content Cookies Our site …
network meta‐analysis - Kew, KM - 2014 | Cochrane Library Skip to Content Cookies Our site …
[HTML][HTML] Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD
Background Long-acting muscarinic antagonist (LAMA)/long-acting β 2-agonist (LABA)
combinations are a treatment option for patients with COPD who continue to have symptoms …
combinations are a treatment option for patients with COPD who continue to have symptoms …
Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD: a systematic literature review
S Zhang, D King, VM Rosen… - International Journal of …, 2020 - Taylor & Francis
With increasing choice of medications and devices for asthma and chronic obstructive
pulmonary disease (COPD) treatment, comparative evidence may inform treatment …
pulmonary disease (COPD) treatment, comparative evidence may inform treatment …
Long-acting muscarinic antagonists
AS Melani - Expert review of clinical pharmacology, 2015 - Taylor & Francis
Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability
worldwide. Inhaled bronchodilators are the mainstay of COPD pharmacological treatment …
worldwide. Inhaled bronchodilators are the mainstay of COPD pharmacological treatment …
Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends
P Montuschi, G Ciabattoni - Journal of medicinal chemistry, 2015 - ACS Publications
Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …
[HTML][HTML] Baseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPD
FJ Martinez, LM Fabbri, GT Ferguson, C Orevillo… - Chest, 2017 - Elsevier
Background The clinical severity of COPD is currently categorized by symptom burden and
exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that …
exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that …
Efficacy of tiotropium+ olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis
GT Ferguson, M Fležar, S Korn, L Korducki… - Advances in …, 2015 - Springer
Introduction The once-daily long-acting muscarinic antagonist (LAMA) tiotropium and once-
daily long-acting β 2-agonist (LABA) olodaterol have been studied as a once-daily fixed …
daily long-acting β 2-agonist (LABA) olodaterol have been studied as a once-daily fixed …
Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled …
R ZuWallack, L Allen, G Hernandez, N Ting… - … journal of chronic …, 2014 - Taylor & Francis
Background Combining bronchodilators with different mechanisms of action may improve
efficacy and reduce risk of side effects compared to increasing the dose of a single agent in …
efficacy and reduce risk of side effects compared to increasing the dose of a single agent in …
New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives
D Singh - British Journal of Clinical Pharmacology, 2015 - Wiley Online Library
Fixed dose combination (FDC) dual bronchodilators that co‐administer a long acting β2‐
adrenoceptor agonist (LABA) and a long acting muscarinic antagonist (LAMA) are a new …
adrenoceptor agonist (LABA) and a long acting muscarinic antagonist (LAMA) are a new …